临床医药文献电子杂志
臨床醫藥文獻電子雜誌
림상의약문헌전자잡지
Journal of Clinical Medical Literature (ElectronicEdition)
2014年
13期
2449-2449
,共1页
贝伐单抗%FOLFIRI化疗方案%转移性结直肠癌
貝伐單抗%FOLFIRI化療方案%轉移性結直腸癌
패벌단항%FOLFIRI화료방안%전이성결직장암
Colorectal neoplasms%FOLFIRI chemotherapy regimen
目的：观察FOLFIRI化疗方案联合贝伐单抗治疗转移性结直肠癌的临床效果。方法选取我院收治的50例转移性结直肠癌患者作为研究对象，随机分为对照组25例予以FOLFIRI化疗治疗，观察组25例予以FOLFIRI化疗方案联合贝伐单抗治疗，比较两组患者的疗效。结果观察组的总有效率96.0%显著优于对照组68.0%，组间差异具有统计学意义（P＜0.05）。结论 FOLFIRI化疗方案联合贝伐单抗治疗转移性结直肠癌疗效显著，改善了患者的生存质量，具有积极的临床推广价值。
目的：觀察FOLFIRI化療方案聯閤貝伐單抗治療轉移性結直腸癌的臨床效果。方法選取我院收治的50例轉移性結直腸癌患者作為研究對象，隨機分為對照組25例予以FOLFIRI化療治療，觀察組25例予以FOLFIRI化療方案聯閤貝伐單抗治療，比較兩組患者的療效。結果觀察組的總有效率96.0%顯著優于對照組68.0%，組間差異具有統計學意義（P＜0.05）。結論 FOLFIRI化療方案聯閤貝伐單抗治療轉移性結直腸癌療效顯著，改善瞭患者的生存質量，具有積極的臨床推廣價值。
목적：관찰FOLFIRI화료방안연합패벌단항치료전이성결직장암적림상효과。방법선취아원수치적50례전이성결직장암환자작위연구대상，수궤분위대조조25례여이FOLFIRI화료치료，관찰조25례여이FOLFIRI화료방안연합패벌단항치료，비교량조환자적료효。결과관찰조적총유효솔96.0%현저우우대조조68.0%，조간차이구유통계학의의（P＜0.05）。결론 FOLFIRI화료방안연합패벌단항치료전이성결직장암료효현저，개선료환자적생존질량，구유적겁적림상추엄개치。
Objective To explore thethe efficacy of bevacizumab plus FOLFIRI for the first line treatment in metastatic colorectal cancer patients Methods 50 cases of metastatic colorectal cancer in our hospital were randomly selected ,Patients were randomly grouped into control group for 25 cases,they were treated with FOLFIRI chemotherapy. The observation group were treated with FOLFIRI chemotherapy and bevacizumab. Results The total efficiency of observation group was 96.0%,better than 68.0%of the control group.There was statistical significance(P<0.05) Conclusion The addition of bevacizumab to FOLFIRI regimen significantly improves the response rate.improve the quality of life of patientsand has clinical application value very positive.
